Anne Kamwila, Healthcare Policy Analyst, explains, To work within the system, your medical expert must submit a detailed Letter of Medical Necessity and a Prior Authorization request
PubMed, Auro, Kirsi, et al
Laboratory investigations continue to optimize peptide formulations, delivery methods, and dosing protocols to enhance research utility and enable investigation of chronic senescent cell elimination effects
These observations led to an interesting development bifurcation : Melanotan I (Afamelanotide) continued as a skin peptide and in 2014 received approval as Scenesse for erythropoietic protoporphyria (a rare genetic disease with severe photosensitivity) Melanotan II was abandoned as a cutaneous drug PT-141 / Bremelanotide , a fragment of Melanotan II targeted at MC4R, was developed as a sexual stimulant and in 2019 approved as Vyleesi for hypoactive sexual desire disorder in women (HSDD) Second life in research and the cosmetic underground Melanotan II never reached commercial approval as a drug, but in the research community and cosmetic underground it became well known
GLP1 medications are recommended conditionally due to cost, access, and long-term data limitations